6[2]Lewis K.O.Poton A.Could Superoxida Cause Cirrhosis.Lancet,1982,2:188
7[3]Roberto Corrcher,M.Casaril,G.Bellisoal,G.B.Gabrielli,N.Nicoli,G.CGuidi.Severe impairment of antioxidant system in human hepeetoma.Cancer,1986,58:1658
2Bolden I,, Wicks MN. Predictors of mental heahh, subjective hurden, and r~,wards in famil~ caregivers of patients with chronic liver disease [ J ]. Arch Psychialr Nurs, 2010, 24(2) : 89-103.
3Blei AT, Cordoba J. Hepalic encephalopalhy [ J ]. Am J Gastroen- terol, 2001, 96(7) : 1968-1976.
4Ojetti V, la~uritano EC, Barbar~ F. et al. Rifaximin pharmacology and ~linic~al implications [J]. Experl Opin Drug Metab Toxicol, 2009, 5 (6) : 675-682.
5Sanyal A, Younossi ZM. Bass NM, et al. Randomised rifaximin improves health-related quality of life clinical trial : patients with hepatic encephalopathy-a douhle-blind placebo-controlled Aliment Pharmacol Ther, 2011 , 34 ( 8 ) : 853-861,.
6Bass NM, Mullen KD, Sanyal AJ, et al. Rifaximin treatment in hepat- ic encephalopathy [J]. N Engl J Med. 2010, 362( 12): 1071-1081.
7Wu D, Wu SW, Lu J, et al. Rifaximin versus nonabsorbable disaceha- rides for/he treatment of hepatic encephalopathy: a Meta-analysis [ J]. Gastroenterol Res Praet, 2013, 2013: 236963.
8Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe anti well tol- erated for long-term maintenance of remission from overt hepatic enceph- alopathy [J]. Clin Gastroenterol Hepatol, 2014, 12(8) : 1390-1397.
